BioSpace News Archive

Cyclophilin Inhibitors Therapeutics Market provides details about the market dynamics affecting the Cyclophilin Inhibitors Therapeutics market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Excipients Market provides details about the market dynamics affecting the Excipients market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Hypertrophic And Keloid Scar Treatment Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Hypertrophic And Keloid Scar Treatment market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the second quarter ended May 31, 2022 and provided a corporate update.

Curis, Inc. announced that on July 5, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 873,750 shares of Curis common stock to sixteen new employees, with a grant date of July 5, 2022.

Haemonetics Corporation announced that the Company intends to publish first quarter fiscal year 2023 financial results at 6:00 am EDT on Wednesday, August 10, 2022.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release second quarter 2022 financial results after market close on Thursday, August 4, 2022.

Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the beginning of dosing in the first United States Food and Drug Administration (FDA)-approved clinical trial studying the effects of naturally derived psychedelic drug candidates.

BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report financial results for its third quarter of fiscal year 2022 on Thursday, August 4, 2022.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter.